All In Biotech

Free tool

FAERS Monitor: Dyrenium

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 013174 or its brand name (Dyrenium, Triamterene). Reports on generic versions are filed under their own applications.

Reports

7,328

Serious

4,003

55% of reports

Hospitalization

1,813

Death reported

414

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • chronic kidney disease479
  • fatigue476
  • drug ineffective453
  • pain439
  • nausea420
  • diarrhoea405
  • dyspnoea348
  • dizziness345
  • renal failure329
  • headache327
  • arthralgia314
  • acute kidney injury308
  • off label use270
  • asthenia261
  • fall259

Reports by year received

View as table
YearReports
2004144
2005178
2006154
2007133
2008152
2009237
2010323
2011295
2012312
2013280
2014384
2015538
2016487
2017475
2018664
2019599
2020405
2021364
2022308
2023237
2024237
2025225
2026197

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,831 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal47918.216.77,749
renal failureSignal3297.16.41,733
acute kidney injurySignal3085.85.21,221
fallSignal2592.22.0178
arthralgiaSignal3142.21.9200
painSignal4392.11.9243
asthenia2612.01.8130
dizziness3452.01.8172
diarrhoea4051.81.6148
dyspnoea3481.81.6118
fatigue4761.81.6160
nausea4201.51.478
headache3271.51.355
drug ineffective4531.00.90
off label use2700.90.84

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.